share_log

Maxim Group Initiates Coverage On Avenue Therapeutics With Buy Rating, Announces Price Target of $0.75

Maxim Group Initiates Coverage On Avenue Therapeutics With Buy Rating, Announces Price Target of $0.75

Maxim集团以买入评级启动对Avenue Therapeutics的报道,宣布目标股价为0.75美元
Benzinga ·  2023/12/11 09:43

Maxim Group analyst Jason McCarthy initiates coverage on Avenue Therapeutics (NASDAQ:ATXI) with a Buy rating and announces Price Target of $0.75.

Maxim集团分析师杰森·麦卡锡以买入评级开始对Avenue Therapeutics(纳斯达克股票代码:ATXI)进行报道,并宣布目标股价为0.75美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发